Polymeric nanoparticles functionalized with peptides: Advanced strategies for crossing the blood-brain barrier.

Q1 Pharmacology, Toxicology and Pharmaceutics
Advances in pharmacology Pub Date : 2026-01-01 Epub Date: 2026-04-24 DOI:10.1016/bs.apha.2026.03.002
X Llorente, G Esteruelas, M L García, E B Souto, E Sánchez-López
{"title":"Polymeric nanoparticles functionalized with peptides: Advanced strategies for crossing the blood-brain barrier.","authors":"X Llorente, G Esteruelas, M L García, E B Souto, E Sánchez-López","doi":"10.1016/bs.apha.2026.03.002","DOIUrl":null,"url":null,"abstract":"<p><p>Targeted drug delivery to the central nervous system (CNS) to tackle brain disorders is hindered by the blood-brain barrier (BBB) which, due to its unique physiology, severely restricts the entry of drugs into the brain. Among the different strategies proposed to overcome the BBB, nanotechnology-based approaches, particularly polymeric nanoparticles (PNPs), have emerged as promising tools. These carriers can protect therapeutic payloads, modulate release profiles, and enhance drug concentration in the CNS. Furthermore, their surfaces can be functionalized with brain shuttle peptides for active targeting strategies. Peptide shuttles recognize specific receptors on the cerebral endothelium, thereby promoting transcytosis and facilitating selective transport into the brain. Peptides functionalizing the surface of PNPs may also increase the interactions between these PNPs and lipid bilayers thereby improving their penetration across the BBB. This chapter discusses the properties and design of peptide-functionalized PNPs, emphasizing how particle size, surface and biodegradability critically influence their performance. Chemical conjugation methods enabling the stable attachment of peptide shuttles are discussed, with particular attention to translational studies addressing major CNS pathologies, including brain tumors, neurodegenerative diseases, and ischemic injuries. Current challenges that determine clinical application, such as variability in synthesis, toxicity, and enzymatic instability, are also critically analysed with the aim of outlining future directions for peptide-mediated drug delivery to the brain.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"105 ","pages":"325-363"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2026.03.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Targeted drug delivery to the central nervous system (CNS) to tackle brain disorders is hindered by the blood-brain barrier (BBB) which, due to its unique physiology, severely restricts the entry of drugs into the brain. Among the different strategies proposed to overcome the BBB, nanotechnology-based approaches, particularly polymeric nanoparticles (PNPs), have emerged as promising tools. These carriers can protect therapeutic payloads, modulate release profiles, and enhance drug concentration in the CNS. Furthermore, their surfaces can be functionalized with brain shuttle peptides for active targeting strategies. Peptide shuttles recognize specific receptors on the cerebral endothelium, thereby promoting transcytosis and facilitating selective transport into the brain. Peptides functionalizing the surface of PNPs may also increase the interactions between these PNPs and lipid bilayers thereby improving their penetration across the BBB. This chapter discusses the properties and design of peptide-functionalized PNPs, emphasizing how particle size, surface and biodegradability critically influence their performance. Chemical conjugation methods enabling the stable attachment of peptide shuttles are discussed, with particular attention to translational studies addressing major CNS pathologies, including brain tumors, neurodegenerative diseases, and ischemic injuries. Current challenges that determine clinical application, such as variability in synthesis, toxicity, and enzymatic instability, are also critically analysed with the aim of outlining future directions for peptide-mediated drug delivery to the brain.

多肽功能化聚合纳米颗粒:跨越血脑屏障的先进策略。
针对中枢神经系统(CNS)治疗脑部疾病的靶向药物递送受到血脑屏障(BBB)的阻碍,血脑屏障由于其独特的生理特性,严重限制了药物进入大脑。在克服血脑屏障的不同策略中,基于纳米技术的方法,特别是聚合物纳米颗粒(PNPs),已经成为有前途的工具。这些载体可以保护治疗有效载荷,调节释放谱,并提高中枢神经系统的药物浓度。此外,它们的表面可以被脑穿梭肽功能化,用于主动靶向策略。肽穿梭体识别脑内皮上的特定受体,从而促进胞吞作用并促进选择性转运到脑内。使PNPs表面功能化的肽也可能增加这些PNPs与脂质双分子层之间的相互作用,从而提高它们在血脑屏障上的渗透。本章讨论了肽功能化PNPs的性质和设计,强调了粒径、表面和生物降解性对其性能的重要影响。讨论了使肽梭稳定附着的化学偶联方法,特别关注针对主要中枢神经系统病理的转化研究,包括脑肿瘤、神经退行性疾病和缺血性损伤。目前决定临床应用的挑战,如合成的变异性、毒性和酶的不稳定性,也被批判性地分析,目的是概述肽介导的药物输送到大脑的未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书